The latest data presented at VIVA21

Physicians and researchers will present groundbreaking findings from late-breaking clinical trials, follow-up data from major randomized trials and registries, and first-in-man experiences with novel devices or drugs.

A limited number of abstracts will be accepted for presentation. Please read the submission guidelines carefully before submitting your abstract for consideration. Accepted late-breaking clinical trials will be presented on Tuesday and Wednesday, October 5 and 6. Each presentation will be followed by a discussion and Q&A with a panel of expert faculty.

Guidelines

The abstract submission deadline is Friday, July 2, at 5pm PDT.

Research must be original and may not have been presented prior to the Late-Breaking Clinical Trial sessions at VIVA21. Abstracts must be submitted electronically via the official VIVA abstract submission website.

Abstract submissions should address areas of endovascular intervention and medicine and can report the results of basic science investigations as well as clinical or pre-clinical studies.

Abstracts must include:

  • Trial name
  • Purpose
  • Materials and methods
  • Results
  • Conclusion

The total abstract length may not exceed 2,500 characters, exclusive of title or figures. The following information must be provided upon submission:

  • Submitter name
  • Primary contact name
  • Organization/institution
  • Phone number
  • Email address
  • Names of up to three authors
  • Name of who will present the abstract, if selected
    • Phone number
    • Email address
  • Name of the company or entity providing funding or research support
  • Six-word title for abstract presentation

Submission Process

Submitted abstracts will be reviewed after the July 2 deadline. Abstracts will be evaluated and scored based on the following criteria:

  • Interest to field
  • Research methods
  • Quality of data
  • Primary endpoint presented

Notification of acceptance or rejection will be sent the week of July 26, 2021. Subsequent communication will provide specifics about submitting the presentation and the date and time of the presentation.

If you have questions please contact Brita Thorne via e-mail: abstracts@vivaphysicians.org

EMBARGO POLICY

Note that for accepted abstracts, VIVA embargoes information presented from becoming public until after the commencement of the Late-Breaking Clinical Trial session as listed in the VIVA21 program or on vivaphysicians.org. No publication, exhibitor, or affiliated company may disseminate information until after the commencement of the Late-Breaking Clinical Trial session in which it is presented.

Enter the submission site